RBC's $22 price target implies an upside of 74% for shares of Biohaven.
Get this delivered to your inbox, and more info about our products and services.
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
The bank pointed to recent M&A success as a catalyst for the stock.
Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
The investment bank upgraded the pharma stock to overweight from equal weight.
RBC analyst Conor McNamara told CNBC the wait might be a little longer.
Carter Worth breaks down the charts on this biotech stock.
